Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "pain"

484 News Found

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D
News | February 02, 2022

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D

The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST


Medtronic gets USFDA approval of spinal cord stimulation therapy
Medical Device | January 25, 2022

Medtronic gets USFDA approval of spinal cord stimulation therapy

Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone


TPVI offers a ray of hope for children with Pulmonic Valve disease
Hospitals | January 18, 2022

TPVI offers a ray of hope for children with Pulmonic Valve disease

Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve


Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
News | January 12, 2022

Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra

Ind-Ra expects revenue growth of over 12% in 2022.


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC


Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
News | January 11, 2022

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia


Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


Pfizer and BioNTech to develop first mRNA-based Shingles vaccine
Biotech | January 07, 2022

Pfizer and BioNTech to develop first mRNA-based Shingles vaccine

Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022


VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer
Startup | December 30, 2021

VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer

The glucometer connects to one’s smartphone and provides actionable diagnostic information


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults